Prostamax
Prostamax is a complex peptide bioregulator preparation derived from prostate tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for research in benign prostatic hyperplasia, prostate aging, and urological health. It belongs to the Cytomed line of peptide bioregulators pioneered by Vladimir Khavinson.
Prostamax is a complex peptide preparation containing a mixture of short peptides extracted from young animal prostate tissue. Unlike single-sequence tetrapeptide bioregulators such as cardiogen or cortagen, prostamax is a multi-peptide complex designed to selectively target prostate gland cells.
Overview
Prostamax is part of a broader research program on peptide bioregulation developed over several decades at the St. Petersburg Institute of Bioregulation and Gerontology. The preparation is derived from prostate tissue of young animals through a process of acid extraction and purification that yields a complex of low-molecular-weight peptides. These peptides are hypothesized to carry tissue-specific regulatory information that can normalize gene expression in aging or damaged prostate cells.
The primary research applications of prostamax center on benign prostatic hyperplasia (BPH), a condition affecting the majority of aging men. Preclinical studies have examined its ability to restore functional parameters of prostate tissue, reduce inflammatory markers, and normalize proliferative activity in prostate epithelial cells.
Mechanism of Action
Prostamax is proposed to act through the general mechanism described for Khavinson's peptide bioregulators: selective interaction with DNA and chromatin structures in target tissue cells, leading to modulation of gene expression. The peptide complex is thought to bind complementary DNA sequences in prostate cell chromatin, influencing transcription of genes involved in cell proliferation, apoptosis, and inflammatory signaling.
In prostate tissue specifically, the bioregulatory effect is hypothesized to normalize the balance between epithelial proliferation and apoptosis that becomes disrupted during BPH development. This may involve regulation of growth factors and their receptors in prostatic stroma and epithelium, as well as modulation of androgen receptor signaling pathways at the transcriptional level.
Khavinson's group has proposed that tissue-specific peptide preparations restore the epigenetic landscape of aging cells toward a younger phenotype, a concept they term "peptide-mediated gene reactivation" (Khavinson & Malinin, 2005).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Benign Prostatic Hyperplasia
Research on prostamax in BPH models has focused on its ability to reduce prostate volume and normalize histological markers of hyperplasia. In animal studies, administration of prostate-derived peptide preparations reduced the ratio of stromal to epithelial tissue and decreased the expression of proliferative markers in prostate cells. Khavinson and colleagues reported that peptide bioregulators targeting prostate tissue could reduce symptoms associated with BPH in aging animal models (Khavinson et al., 2003, Bull Exp Biol Med).
Prostate Aging and Cellular Senescence
The peptide complex has been studied in the context of age-related changes in prostate tissue. Research demonstrated that prostate-derived peptides modulated the expression of senescence-associated markers in cultured prostate fibroblasts, including changes in cytokine secretion profiles characteristic of the senescence-associated secretory phenotype (SASP). This work builds on broader findings by Kheifets et al. (2010) on peptidergic regulation of fibroblast signaling in the prostate gland during cellular aging.
Combined Bioregulator Approaches
Several studies from the St. Petersburg group have examined prostamax in combination with other peptide bioregulators. The rationale is that complex age-related conditions may benefit from multi-tissue targeting. Combinations of prostamax with epithalon (pineal gland bioregulator) and other preparations have been explored in aging cohorts, with reported improvements in urological function parameters (Khavinson, 2002, Neuro Endocrinol Lett).
Safety Profile
Prostamax has been used in Russia as a dietary supplement (Cytomed product line) for over a decade. No significant adverse effects have been reported in the available literature. As a complex of naturally derived short peptides, it is expected to have low toxicity. However, formal controlled clinical safety studies meeting international regulatory standards have not been published. Men with diagnosed prostate cancer should not use prostate-targeted bioregulators without medical supervision, given the theoretical concern of stimulating proliferative pathways.
Pharmacokinetic Profile
- Half-life
- Not established
- Tmax
- Side effects: Mild injection site reactions possible
Quick Start
- Typical Dose
- 10-20mg daily
- Frequency
- Daily for 10-20 days per cycle
- Route
- Oral (capsules)
- Cycle Length
- 10-20 days
- Storage
- Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated
Molecular Structure
- Formula
- Not applicable (multi-peptide preparation)
- Weight
- 473 Da
- Length
- 4 amino acids
- CAS
- Not available
- PubChem CID
- 9848296
- Exact Mass
- 487.2278 Da
- LogP
- -9
- TPSA
- 242 Ų
- H-Bond Donors
- 7
- H-Bond Acceptors
- 11
- Rotatable Bonds
- 15
- Complexity
- 776
Identifiers (SMILES, InChI)
InChI=1S/C20H33N5O9/c21-8-2-1-4-11(22)17(30)23-12(6-7-15(26)27)18(31)24-13(10-16(28)29)19(32)25-9-3-5-14(25)20(33)34/h11-14H,1-10,21-22H2,(H,23,30)(H,24,31)(H,26,27)(H,28,29)(H,33,34)/t11-,12-,13-,14-/m0/s1
WUCUNGRTSFLCLI-XUXIUFHCSA-NResearch Indications
Prostate Health
Research shows reduced inflammation and swelling in prostatitis models.
Mitigates inflammation and immune cell infiltration in prostate tissue.
Decreases scarring and pathological remodeling in prostate.
Anti-Aging
Promotes deheterochromatinization in elderly cells.
Potentially reactivates genes repressed during aging process.
Normalizes age-related changes in lymphocyte function.
Research Protocols
oral
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | —(Route: Oral capsules) |
subcutaneous Injection
Injectable form available for direct administration.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Research protocol | 10 mg | Daily for 10-15 days | —(Route: IM or SubQ) |
Reconstitution Guide (mg vial + mL BAC water)
- Clean work area thoroughly
- Reconstitute with appropriate volume
- Gently swirl until dissolved
- Store reconstituted solution refrigerated
intramuscular Injection
Prostate bioregulator administered intramuscularly. Rotate among deltoid, vastus lateralis, and gluteus.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Loading phase | 500 mcg (0.5 mg) | Once daily IM | Weeks 1-2 |
| Escalation | 750 mcg | Once daily IM | Weeks 3-4 |
| Standard dose | 1,000 mcg (1 mg) | Once daily IM | Weeks 5-8 |
| Maintenance | 1,000 mcg (1 mg) | Once daily IM | Weeks 9-12(Cycle 8-12 weeks, extendable to 16) |
Reconstitution Guide (20mg vial + 2mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 2.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 10 mg/mL
- For 500 mcg (0.5 mg) dose: draw 5 units (0.05 mL)
- For 750 mcg dose: draw 7.5 units (0.075 mL)
- For 1,000 mcg (1 mg) dose: draw 10 units (0.10 mL)
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
Combinations of prostamax with epithalon (pineal gland bioregulator) and other preparations have been explored in aging cohorts, with reported improvements in urological function parameters (Khavinson, 2002, Neuro Endocrinol Lett).
What to Expect
What to Expect
Chromatin remodeling and gene expression changes begin
Effects persist due to epigenetic changes
Prostate function improvements
Cumulative benefits with periodic cycles
Safety Profile
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Contraindications
- Prostate cancer (consult oncologist)
- Known hypersensitivity
- Pregnancy (not applicable)
Discontinue If
- Allergic reactions
- Unusual urinary symptoms
Quality Indicators
What to look for
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Caution
- Unknown source or purity
Red flags
- Discoloration
- Unusual odor
- Damaged packaging
Frequently Asked Questions
References (10)
- [2]Khavinson VKh (2002). Peptides and ageing. Neuro Endocrinol Lett (2002)
- [4]Khavinson Peptide Bioregulators (2020)
- [3]Deheterochromatinization of Chromatin in Old Age Induced by Oligopeptide Bioregulator (Lys-Glu-Asp-Pro) (2012)
- [1][Khavinson VKh & Malinin VV (2005). Gerontological aspects of genome peptide regulation. Karger (2005)
- [4]Kheifets OV, Poliakova VO, Kvetnoĭ IM (2010). Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging. Adv Gerontol (Uspekhi Gerontol) (2010)
- [1]Experimental Studying of Drug Efficiency Prostamax in Therapy of Chronic Aseptic Prostatitis (2013)
- [3]Khavinson VKh et al. (2003). Effects of peptide bioregulators on prostate tissue in aging. Bull Exp Biol Med (2003)
- [10]Khavinson VKh et al Short peptides: regulation of gene activity and application in gerontology. Adv Gerontol (2021)
- [2]
- [5][Khavinson V et al. (2020). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung (2020)
Progestogen Peptide Mimetics
Progestogen peptide mimetics are an emerging class of research-stage compounds designed to selectively modulate the progesterone receptor using peptide-based scaffolds rather than traditional steroid backbones, with potential applications in endometrial protection during HRT, non-steroidal contraception, and management of uterine fibroids and endometriosis.
Protegrin-1 (PG-1)
Protegrin-1 is an 18-amino acid beta-hairpin antimicrobial peptide from porcine leukocytes, featuring two disulfide bonds and potent broad-spectrum antimicrobial activity through membrane pore formation. Its synthetic analog iseganan (IB-367) has been evaluated in clinical trials.